HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy.

Abstract
Gene activation requires cooperative assembly of multiprotein transcription factor-coregulator complexes. Disruption to cooperative assemblage could underlie repression of tumor suppressor genes in leukemia cells. Mechanisms of cooperation and its disruption were therefore examined for PU.1 and RUNX1, transcription factors that cooperate to activate hematopoietic differentiation genes. PU.1 is highly expressed in leukemia cells, whereas RUNX1 is frequently inactivated by mutation or translocation. Thus, coregulator interactions of Pu.1 were examined by immunoprecipitation coupled with tandem mass spectrometry/Western blot in wild-type and Runx1-deficient hematopoietic cells. In wild-type cells, the NuAT and Baf families of coactivators coimmunoprecipitated with Pu.1. Runx1 deficiency produced a striking switch to Pu.1 interaction with the Dnmt1, Sin3A, Nurd, CoRest, and B-Wich corepressor families. Corepressors of the Polycomb family, which are frequently inactivated by mutation or deletion in myeloid leukemia, did not interact with Pu.1. The most significant gene ontology association of Runx1-Pu.1 co-bound genes was with macrophages, therefore, functional consequences of altered corepressor/coactivator exchange were examined at Mcsfr, a key macrophage differentiation gene. In chromatin immunoprecipitation analyses, high level Pu.1 binding to the Mcsfr promoter was not decreased by Runx1 deficiency. However, the Pu.1-driven shift from histone repression to activation marks at this locus, and terminal macrophage differentiation, were substantially diminished. DNMT1 inhibition, but not Polycomb inhibition, in RUNX1-translocated leukemia cells induced terminal differentiation. Thus, RUNX1 and PU.1 cooperate to exchange corepressors for coactivators, and the specific corepressors recruited to PU.1 as a consequence of RUNX1 deficiency could be rational targets for leukemia differentiation therapy.
AuthorsXiaorong Gu, Zhenbo Hu, Quteba Ebrahem, John S Crabb, Reda Z Mahfouz, Tomas Radivoyevitch, John W Crabb, Yogen Saunthararajah
JournalThe Journal of biological chemistry (J Biol Chem) Vol. 289 Issue 21 Pg. 14881-95 (May 23 2014) ISSN: 1083-351X [Electronic] United States
PMID24695740 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Copyright© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.
Chemical References
  • Co-Repressor Proteins
  • Core Binding Factor Alpha 2 Subunit
  • Proto-Oncogene Proteins
  • Trans-Activators
  • proto-oncogene protein Spi-1
Topics
  • Animals
  • Blotting, Western
  • Cell Differentiation (genetics)
  • Cells, Cultured
  • Chromatin Immunoprecipitation
  • Co-Repressor Proteins (genetics, metabolism)
  • Core Binding Factor Alpha 2 Subunit (genetics, metabolism)
  • Gene Expression Profiling
  • HEK293 Cells
  • Humans
  • Leukemia (genetics, metabolism, pathology)
  • Macrophages (metabolism)
  • Mice
  • Mice, Knockout
  • Mutation
  • Oligonucleotide Array Sequence Analysis
  • Protein Binding
  • Proto-Oncogene Proteins (genetics, metabolism)
  • Tandem Mass Spectrometry
  • Trans-Activators (genetics, metabolism)
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: